6/16/2011 7:27:07 AM
A vaccine developed by Serum Institute of India Ltd., led by billionaire Cyrus Poonawalla, was better at protecting people from a strain of meningitis in sub-Saharan Africa than older products from companies including GlaxoSmithKline Plc (GSK), researchers said.
About 600 children under two years old were given the vaccines and their immunity levels tested four weeks and 10 months after the inoculation. More than 96 percent of those who received Serum’s MenAfriVac had high levels of antibodies in their blood after four weeks, compared with 64 percent in the group that got Glaxo’s Mencevax Acwy, scientists wrote in a paper published in the New England Journal of Medicine today.
comments powered by